trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['lung', 'nsclc', 'sclc', 'trastuzumab deruxtecan']
importantly- interstitial lung disease much less frequent at the 5.4 mg/kg dose (5.9%, only 1 case of g3). this is the fda approved dose of trastuzumab deruxtecan in #her2 nsclc #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him